- Y Diweddaraf sydd Ar Gael (Diwygiedig)
- Gwreiddiol (a wnaed Fel)
The Medical Devices (Northern Ireland Protocol) Regulations 2021
You are here:
Pa Fersiwn
Nodweddion Uwch
- Dangos Graddfa Ddaearyddol(e.e. Lloegr, Cymru, Yr Alban aca Gogledd Iwerddon)
- Dangos Llinell Amser Newidiadau
Rhagor o Adnoddau
Changes to legislation:
There are currently no known outstanding effects for the The Medical Devices (Northern Ireland Protocol) Regulations 2021, SCHEDULE 3.
Changes to Legislation
Revised legislation carried on this site may not be fully up to date. At the current time any known changes or effects made by subsequent legislation have been applied to the text of the legislation you are viewing by the editorial team. Please see ‘Frequently Asked Questions’ for details regarding the timescales for which new effects are identified and recorded on this site.
Regulation 23
SCHEDULE 3N.I.Provisions breach of which is an offence under regulation 23
This
Atodlen has no associated
Memorandwm Esboniadol
Commencement Information
I1Sch. 3 in force at 27.7.2021, see reg. 1(2)
[F1Table 1
| Regulation | Title of the regulation |
|---|---|
| 5 | Reprocessing of single-use devices |
| 6 | Requirement on health institutions relating to implanted devices |
| 7 | Provision of information relating to custom-made devices |
| 9 | Retention of documentation relating to conformity assessments and custom-made devices |
| 10 | UK(NI) indication under Regulation (EU) 2017/745 |
| 10B | Retention of documentation relating to conformity assessments |
| 10C | UK(NI) indication under Regulation (EU) 2017/746 |
| 11 | Ethical review of clinical investigations |
| 12(1) | Prior authorisation of clinical investigations by the Secretary of State |
| 14 | Damage compensation in relation to clinical investigations |
| 15 | Retention of documentation relating to clinical investigations |
| 17C | Ethical review of performance studies |
| 17E | Damage compensation in relation to performance studies |
| 17F | Retention of documentation relating to performance studies] |
Textual Amendments
F1Sch. 3 Table 1 substituted (21.3.2024) by The Medical Devices (In Vitro Diagnostic Devices etc.) (Amendment) Regulations 2024 (S.I. 2024/221), regs. 1(2), 44(a)
Table 2
| Article | Title of the article |
|---|---|
| 5(1) to (3), (5) | Placing on the market and putting into service |
| 6(1)-(3) | Distance sales |
| 7 | Claims |
| 9(3), (4) | Common specifications |
| 10 (except in paragraph 14, only the first sub-paragraph) | [F2general obligations of manufacturers] |
| 11(1), (3), (6) | Authorised representative |
| 12 | Change of authorised representative |
| 13 | General obligations of importers |
| 14 | General obligations of distributors |
| 15 | Person responsible for regulatory compliance |
| 16(3), (4) | Cases in which obligations of manufacturers apply to importers, distributors or other persons. |
| 17(1) | Single-use devices and their reprocessing |
| 18(1) | Implant card and information to be supplied to the patient with an implanted device |
| 21(2) | Devices for special purposes |
| 22(1), (3) to (5) | Systems and procedure packs |
| 23(1) | Parts and components |
| 25(1), (2) | Identification within the supply chain |
| [F332(1) (except the second sentence of the third sub-paragraph), (2)] | Summary of safety and clinical performance |
| 52(1) to (4), (6) to (11), (13) | Conformity assessment procedures |
| 53(3) | Involvement of notified bodies in conformity assessment procedures |
| 58(1) | Voluntary change of notified body |
| 62(1), (2) (only the first sub-paragraph), (3) (only the first sub-paragraph), (4), (5), (7) | General requirements regarding clinical investigations conducted to demonstrate conformity of devices |
| 82(1) | Requirements regarding other clinical investigations |
| 84 | Post-market surveillance plan |
| 85 | Post-market surveillance report |
| [F486 (except the second and third sentences of paragraph (2))] | Periodic safety update report |
| 89(1), (3) (only the second sub-paragraph),(5), (8) | Analysis of serious incidents and field safety corrective actions |
| 94 (only the final paragraph) | Evaluation of devices suspected of presenting an unacceptable risk or other non-compliance |
Textual Amendments
F2Words in Sch. 3 Table 2 substituted (21.3.2024) by The Medical Devices (In Vitro Diagnostic Devices etc.) (Amendment) Regulations 2024 (S.I. 2024/221), regs. 1(2), 44(b)(i)
F3Words in Sch. 3 Table 2 substituted (21.3.2024) by The Medical Devices (In Vitro Diagnostic Devices etc.) (Amendment) Regulations 2024 (S.I. 2024/221), regs. 1(2), 44(b)(ii)
F4Words in Sch. 3 Table 2 substituted (21.3.2024) by The Medical Devices (In Vitro Diagnostic Devices etc.) (Amendment) Regulations 2024 (S.I. 2024/221), regs. 1(2), 44(b)(iii)
[F5Table 3
| Article | Title of the article |
|---|---|
| 5(1) to (3), (5) | Placing on the market and putting into service |
| 6(1) to (3) | Distance sales |
| 7 | Claims |
| 9(3) | Common specifications |
| 10 (except the second, third or fourth sub-paragraphs of paragraph 13) | General obligations of manufacturers |
| 11(1), (3), (6) | Authorised representative |
| 12 | Change of authorised representative |
| 13 | General obligations of importers |
| 14 | General obligations of distributors |
| 15 | Person responsible for regulatory compliance |
| 16(3), (4) | Cases in which obligations of manufacturers apply to importers, distributors or other persons |
| 20(1) | Parts and components |
| 22 | Identification within the supply chain |
| 29(1) (except the second sentence of the third sub-paragraph), (2) | Summary of safety and performance |
| 48(1), (2), (3) (except the third sub-paragraph), (4) (except the second sub-paragraph), (7) (except the third sub-paragraph), (8) (except the second sub-paragraph), (9) and (10) | Conformity assessment procedures |
| 49(3) | Involvement of notified bodies in conformity assessment procedures |
| 53(1) | Voluntary change of notified body |
| 57 | General requirements regarding performance studies |
| 58(1), (2), (4) (except the second sub-paragraph), (5), (6) and (8) | Additional requirements for certain performance studies |
| 79 | Post-market surveillance plan |
| 80 | Post-market surveillance report |
| 81 (except the second and third sentences of paragraph (2)) | Periodic safety update report |
| 84(1), (3) (except the first sub-paragraph), (5) and (8) | Analysis of serious incidents and field safety corrective actions |
| 89 (only the final paragraph) | Evaluation of devices suspected of presenting an unacceptable risk or other non-compliance] |
Textual Amendments
F5Sch. 3 Table 3 inserted (21.3.2024) by The Medical Devices (In Vitro Diagnostic Devices etc.) (Amendment) Regulations 2024 (S.I. 2024/221), regs. 1(2), 44(c)
Options/Help
Print Options
PrintThe Whole Instrument
PrintThis Schedule only
Mae deddfwriaeth ar gael mewn fersiynau gwahanol:
Y Diweddaraf sydd Ar Gael (diwygiedig):Y fersiwn ddiweddaraf sydd ar gael o’r ddeddfwriaeth yn cynnwys newidiadau a wnaed gan ddeddfwriaeth ddilynol ac wedi eu gweithredu gan ein tîm golygyddol. Gellir gweld y newidiadau nad ydym wedi eu gweithredu i’r testun eto yn yr ardal ‘Newidiadau i Ddeddfwriaeth’.
Gwreiddiol (Fel y’i Deddfwyd neu y’i Gwnaed): Mae'r wreiddiol fersiwn y ddeddfwriaeth fel ag yr oedd pan gafodd ei deddfu neu eu gwneud. Ni wnaed unrhyw newidiadau i’r testun.
Gweler y wybodaeth ychwanegol ochr yn ochr â’r cynnwys
Rhychwant ddaearyddol: Indicates the geographical area that this provision applies to. For further information see ‘Frequently Asked Questions’.
Dangos Llinell Amser Newidiadau: See how this legislation has or could change over time. Turning this feature on will show extra navigation options to go to these specific points in time. Return to the latest available version by using the controls above in the What Version box.
Dewisiadau Agor
Dewisiadau gwahanol i agor deddfwriaeth er mwyn gweld rhagor o gynnwys ar y sgrin ar yr un pryd
Memorandwm Esboniadol
Mae Memoranda Esboniadol yn nodi datganiad byr o ddiben Offeryn Statudol ac yn rhoi gwybodaeth am ei amcan polisi a goblygiadau polisi. Maent yn ceisio gwneud yr Offeryn Statudol yn hygyrch i ddarllenwyr nad oes ganddynt gymhwyster cyfreithiol, ac maent yn cyd-fynd ag unrhyw Offeryn Statudol neu Offeryn Statudol Drafft a gyflwynwyd ger bron y Senedd o Fehefin 2004 ymlaen.
Rhagor o Adnoddau
Gallwch wneud defnydd o ddogfennau atodol hanfodol a gwybodaeth ar gyfer yr eitem ddeddfwriaeth o’r tab hwn. Yn ddibynnol ar yr eitem ddeddfwriaeth sydd i’w gweld, gallai hyn gynnwys:
- y PDF print gwreiddiol y fel deddfwyd fersiwn a ddefnyddiwyd am y copi print
- rhestr o newidiadau a wnaed gan a/neu yn effeithio ar yr eitem hon o ddeddfwriaeth
- manylion rhoi grym a newid cyffredinol
- pob fformat o’r holl ddogfennau cysylltiedig
- slipiau cywiro
- dolenni i ddeddfwriaeth gysylltiedig ac adnoddau gwybodaeth eraill
Llinell Amser Newidiadau
This timeline shows the different points in time where a change occurred. The dates will coincide with the earliest date on which the change (e.g an insertion, a repeal or a substitution) that was applied came into force. The first date in the timeline will usually be the earliest date when the provision came into force. In some cases the first date is 01/02/1991 (or for Northern Ireland legislation 01/01/2006). This date is our basedate. No versions before this date are available. For further information see the Editorial Practice Guide and Glossary under Help.
Rhagor o Adnoddau
Defnyddiwch y ddewislen hon i agor dogfennau hanfodol sy’n cyd-fynd â’r ddeddfwriaeth a gwybodaeth am yr eitem hon o ddeddfwriaeth. Gan ddibynnu ar yr eitem o ddeddfwriaeth sy’n cael ei gweld gall hyn gynnwys:
- y PDF print gwreiddiol y fel gwnaed fersiwn a ddefnyddiwyd am y copi print
- slipiau cywiro
liciwch ‘Gweld Mwy’ neu ddewis ‘Rhagor o Adnoddau’ am wybodaeth ychwanegol gan gynnwys
- rhestr o newidiadau a wnaed gan a/neu yn effeithio ar yr eitem hon o ddeddfwriaeth
- manylion rhoi grym a newid cyffredinol
- pob fformat o’r holl ddogfennau cysylltiedig
- dolenni i ddeddfwriaeth gysylltiedig ac adnoddau gwybodaeth eraill
Mae’r holl gynnwys ar gael dan Drwydded Llywodraeth Agored v3.0 ac eithrio ble nodir yn wahanol. Yn ychwanegol mae’r safle hwn â chynnwys sy’n deillio o EUR-Lex, a ailddefnyddiwyd dan delerau Penderfyniad y Comisiwn 2011/833/EU ar ailddefnyddio dogfennau o sefydliadau’r UE. Am ragor o wybodaeth gweler ddatganiad cyhoeddus Swyddfa Gyhoeddiadau’r UE ar ailddefnyddio.